Vitamin K2 Protects Against Glucocorticoid-Induced Osteoporosis by Activating the NRF2/FSP1 Pathway to Inhibit Osteoblast Ferroptosis
Drug Design, Development and Therapy · 2025-12 · Volume 19 · 11525-11545
DOI: 10.2147/dddt.s554610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-12. Verfasst von Zhichao Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral…. Hauptthemen laut MEDLINE: Ferroptosis, NF-E2-Related Factor 2, Osteoblasts, Osteoporosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and its pathogenesis is closely associated with oxidative stress and impaired osteogenic differentiation. Vitamin K2 (VK2) has strong antioxidant properties and potent bone-forming effects, but its application in GIOP is still unclear. This study investigates the therapeutic potential of VK2 in GIOP and elucidates its underlying molecular mechanisms.
Methods
Dexamethasone (DEX) was used to establish GIOP model within C57BL/6 mice. The bone mass was assessed using micro-computed tomography (micro-CT), hematoxylin and eosin (HE) staining, and Masson's trichrome staining in vivo. The osteoblast activity and the expression of osteogenic and ferroptosis-related markers were evaluated via immunohistochemistry (IHC), RT-qPCR, Western blotting, ALP and alizarin red staining. The mitochondrial function and lipid peroxidation of MC3T3-E1 cells were detected by flow cytometry, immunofluorescence and specific kits.
Results
VK2 partially prevented bone mass reduction and osteoblast activity inhibition in GIOP mice. VK2 not only reversed the DEX-induced reductions in Tb.N, BV/TV, and Tb.Th, but also significantly increased the expression of osteogenic markers, including OCN and ALP (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental…
- Department of Orthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China.
- Center of Osteoporosis and Bone Mineral Research, Shandong University, Jinan, Shandong, People's Republic of China.
- Department of Stomatology, The Second Hospital of Shandong University, Jinan, Shandong, People's Republic of China.
- School of Stomatology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.
ORCID-Profile: Yuying Kou, Jie Guo, Minqi Li
Zitieren
APA
Zhang, Z., Rong, X., Ren, Q., Kou, Y., Guo, J., & Li, M. (2025). Vitamin K2 Protects Against Glucocorticoid-Induced Osteoporosis by Activating the NRF2/FSP1 Pathway to Inhibit Osteoblast Ferroptosis. Drug Design, Development and Therapy, Volume 19, 11525-11545. https://doi.org/10.2147/dddt.s554610
Vancouver
Zhang Z, Rong X, Ren Q, Kou Y, Guo J, Li M. Vitamin K2 Protects Against Glucocorticoid-Induced Osteoporosis by Activating the NRF2/FSP1 Pathway to Inhibit Osteoblast Ferroptosis. Drug Design, Development and Therapy. 2025;Volume 19:11525-11545. doi:10.2147/dddt.s554610
BibTeX
@article{Zhang2025,
author = {Zhang, Zhichao and Rong, Xing and Ren, Qinghua and Kou, Yuying and Guo, Jie and Li, Minqi},
title = {Vitamin K2 Protects Against Glucocorticoid-Induced Osteoporosis by Activating the NRF2/FSP1 Pathway to Inhibit Osteoblast Ferroptosis},
journal = {Drug Design, Development and Therapy},
year = {2025},
volume = {Volume 19},
pages = {11525--11545},
doi = {10.2147/dddt.s554610}
}
EUVIMED